HIV remains incurable but manageable. Johns Hopkins found a way to silence it long-term using a molecule from the virus itself, offering hope for future gene therapy without daily meds.

Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company, held its 2025 Annual Shareholders' Meeting today, chaired by Chairman Mr. Benny T. Hu. The company delivered updates ...

Yeztugo (lenacapavir) will be the first option that gives people who need or want PrEP the option of injecting only twice a ...

Medical tests on the Bangladeshi women rescued recently from an inter-state prostitution racket operating across the city ...

In a significant breakthrough, scientists at Johns Hopkins University have discovered that gene therapy could be a key to forcing HIV into a permanent dormant state, potentially offering a long-term, ...

Preventative therapies for HIV-1 (Human Immunodeficiency Virus type 1) have made leaps and bounds over the past decade. A ...

The national rollout program continues to expand, with more vending machines to be installed in Australian universities, in NSW, South Australia and Victoria. Vending machines have also been rolled ...

Gilead Sciences (NasdaqGS:GILD) recently entered an exclusive agreement with Kymera Therapeutics to advance a molecular glue degrader program targeting CDK2, enhancing its oncology pipeline.

The US has approved lenacapavir for HIV prevention. However, experts worry that cuts to the health budget will "squander" the drug's chance of reducing infections.

There are two ways that HIV patients’ bodies can keep the virus under control after they stop antiretroviral therapy, a new ...

The Food and Drug Administration has approved a drug that reduces the chances of contracting HIV. A University of Utah ...

In 2023, a clinical trial began in South Africa and the US to test the efficacy of a potential vaccine against HIV called VIR-1388. Like other vaccines, VIR-1388 would not be a cure for HIV but, if it ...